NEW YORK, Aug. 5 (Xinhua) -- U.S. pharmaceutical company Pfizer announced its second-quarter earnings on Tuesday, reporting a 10 percent year over year operational growth.
The financial results posted by the New York-headquartered company represent revenue of 14.7 billion U.S. dollars or 0.51 dollars of earnings per share.
In an upward revision of its full-year guidance, Pfizer said it now expects adjusted earnings per share for 2025 to range between 2.90 dollars and 3.10 dollars, compared to its previous forecast of 2.80 dollars to 3.00 dollars.
The company maintained its annual revenue projection of 61 billion to 64 billion dollars, reflecting confidence in its underlying business performance.
"Our business is performing well and I'm pleased with the progress we achieved in the second quarter," Pfizer Chairman and CEO Albert Bourla said in a statement.
Pfizer's strong performance came amid mounting policy pressures from the White House. U.S. President Donald Trump has recently sent letters to 17 pharmaceutical companies, including Pfizer, demanding that they cut prices on all existing medications for Medicaid patients to levels no higher than those in Europe.
During Tuesday's earnings call, Bourla acknowledged that the company received the letter from the Trump administration. However, he declined to elaborate on the policy's specific impacts, although he emphasized that discussions with the administration have been "extremely productive."
Pfizer's Q2 results were bolstered by rising sales in several key product categories. Its Vyndaqel line of cardiomyopathy treatments showed solid growth, and COVID-19-related products were major contributors.
